Suven Life Sciences Ltd
Suven Life Sciences Ltd (SUVEN) last reported results for the quarter ended Jun 2026, with sales of ₹4 crore and net profit of ₹-128 crore. The stock last traded at ₹305, a market capitalisation of ₹8,613 crore. Over the past 52 weeks the stock has ranged between ₹124 and ₹403. Figures are as of 6 Oct 2026 and are not real time.
Suven Life Sciences Ltd share price and key metrics
- Current price
- ₹305
- Market cap
- ₹8,613 cr
- Book value
- ₹22.4
- ROE
- -81.5%
- ROCE
- -79.5%
- Dividend yield
- 0.00%
- 52w high / low
- 403/124
Metrics as of 6 Oct 2026. Not real time.
Track Suven Life Sciences Ltd
Cruxal reads every Suven Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Suven Life Sciences Ltd growth and returns
- 10 Years
- -35%
- 5 Years
- -12%
- 3 Years
- -19%
- TTM
- 17%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -91%
- 10 Years
- 37%
- 5 Years
- 23%
- 3 Years
- 62%
- 1 Year
- 46%
- 10 Years
- -24%
- 5 Years
- -68%
- 3 Years
- -66%
- Last Year
- -82%
Suven Life Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4 cr, up 100.0% from ₹2 cr a year earlier. Net profit was ₹-128 cr, down 146.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Expenses | 55 | 41 | 45 | 53 | 81 | 106 | 52 | 136 |
| Operating profit | -52 | -39 | -44 | -51 | -80 | -103 | -51 | -132 |
| OPM % | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | -3,711% |
| Other income | 4 | 2 | 1 | 1 | 4 | 3 | 7 | 8 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net profit | -50 | -39 | -44 | -52 | -77 | -102 | -46 | -128 |
| EPS (₹) | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | -4.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Suven Life Sciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 543 | 625 | 286 | 13 | 13 | 12 | 14 | 12 | 7 | 7 | 9 |
| Operating profit | 129 | 198 | -14 | -116 | -80 | -122 | -126 | -128 | -166 | -284 | -366 |
| OPM % | 24% | 32% | -5% | -917% | -593% | -1,032% | -929% | -1,094% | -2,487% | -3,999% | -4,152% |
| Net profit | 87 | 124 | -24 | -94 | -72 | -122 | -118 | -105 | -161 | -276 | -352 |
| EPS (₹) | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | -5.59 | -5.42 | -4.82 | -7.37 | -10.48 | -14.44 |
TTM is the trailing twelve months to the most recent quarter.
Suven Life Sciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 | 22 | 26 |
| Reserves | 654 | 755 | 226 | 131 | 95 | 82 | 354 | 248 | 88 | 565 |
| Borrowings | 71 | 34 | 3 | 6 | 5 | 3 | 2 | 1 | 0 | 17 |
| Other liabilities | 78 | 118 | 62 | 33 | 16 | 9 | 12 | 14 | 25 | 16 |
| Total liabilities | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
| Fixed assets | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 | 60 | 73 |
| CWIP | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 4 |
| Investments | 301 | 279 | 223 | 0 | 0 | 45 | 46 | 76 | 22 | 181 |
| Other assets | 199 | 308 | 58 | 157 | 103 | 22 | 305 | 181 | 53 | 367 |
| Total assets | 816 | 919 | 303 | 182 | 128 | 108 | 389 | 285 | 135 | 624 |
As reported by the company. Total assets equal total liabilities by construction.
Suven Life Sciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 109 | 70 | -53 | -135 | -96 | -128 | -116 | -115 | -155 | -300 |
| Cash from investing | -311 | -1 | 30 | 146 | 56 | -22 | -248 | 94 | 155 | -462 |
| Cash from financing | -30 | -52 | 5 | 3 | 35 | 146 | 396 | -1 | -1 | 757 |
| Net cash flow | -232 | 17 | -18 | 14 | -5 | -4 | 32 | -22 | -1 | -5 |
| Free cash flow | 79 | 28 | -92 | -137 | -102 | -147 | -119 | -113 | -193 | -305 |
| CFO / operating profit | 111% | 57% | 262% | 114% | 119% | 104% | 91% | 95% | 93% | 106% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Suven Life Sciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 15% | 24% | -4% | -54% | -58% | -118% | -53% | -36% | -87% | -80% |
| Debtor days | 31 | 36 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Inventory days | 222 | 329 | 0 | — | — | — | — | — | — | — |
| Days payable | 91 | 134 | — | — | — | — | — | — | — | — |
| Cash conversion cycle | 162 | 231 | 3 | 66 | 48 | 40 | 22 | 40 | 73 | 78 |
| Working capital days | 42 | 82 | 23 | 704 | 1,084 | 234 | 265 | 101 | -440 | 506 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Suven Life Sciences Ltd shareholding pattern
Promoters held 65.47% at Jul 2026, down from 67.36% at Sep 2025. FIIs 0.48% and DIIs 2.73%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 70.26% | 70.26% | 70.26% | 67.36% | 67.36% | 70.15% | 70.08% | 65.47% |
| FIIs | 0.34% | 0.25% | 0.58% | 1.17% | 1.07% | 0.91% | 0.56% | 0.48% |
| DIIs | 1.05% | 0.01% | 0.03% | 3.39% | 3.39% | 4.62% | 2.93% | 2.73% |
| Public | 28.35% | 29.47% | 29.12% | 28.07% | 28.18% | 24.32% | 26.42% | 31.32% |
| No. of shareholders | 63,537 | 64,603 | 66,159 | 64,921 | 64,381 | 63,915 | 66,791 | 66,647 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Suven Life Sciences Ltd corporate filings
- Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- Closure of Trading WindowInsider Trading / SASTlow impact
- Suven Life Sciences releases routine media updateCompany Updatelow impact
Cruxal's analysis: Suven Life Sciences has filed a press release under Regulation 30 of the LODR. The…
Read the full analysis - Suven Life Sciences Limited concludes 37th AGM; shareholders approve variation in utilization of funds raised through preferential issueAGM/EGMlow impact
Cruxal's analysis: Suven Life Sciences Limited has successfully concluded its 37th Annual General Meeting…
Read the full analysis - Suven Life Sciences files Monitoring Agency Report for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: The company has submitted its Monitoring Agency Report for the quarter ended June 30…
Read the full analysis - Suven Life Sciences Reports Continued Financial Losses for Quarter Ended June 30, 2026Company Updatemedium impact
Cruxal's analysis: Suven Life Sciences Limited has released its unaudited financial results for the quarter…
Read the full analysis - Suven Life Sciences reports Q1 FY27 consolidated net loss of 127.61 crore amid heavy R&D investmentBoard Meetingmedium impact
Cruxal's analysis: Suven Life Sciences Limited reported a consolidated net loss of 127.61 crore for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.